AN2 Therapeutics, Inc.
ANTXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$38.1M | −$56.8M | −$69.6M | −$42.3M | −$21.6M |
| Net income | −$35.2M | −$51.3M | −$64.7M | −$41.0M | −$21.5M |
| Total assets | $62.0M | $92.1M | $138.7M | $102.6M | $65.3M |
| Total liabilities | $8.9M | $10.2M | $14.0M | $7.2M | $3.4M |
| Equity | $53.1M | $81.8M | $124.7M | $95.4M | −$47.4M |
| EPS (diluted) | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $-10.64 |
| Shares out. | 30.1M | 29.8M | 19.4M | 19.4M | 2.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −66.3%
- Return on assets
- −56.8%
- Return on capital (ROCE)
- −71.6%
- Liabilities / assets
- 14.4%
- Debt / equity
- 0.17×
- Book value / share
- $1.76
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.12distress
- Accruals / assets
- −8.6%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Almitas Capital LlcPassive (13G)May 15, 2026
- Commodore Capital LpPassive (13G)Mar 16, 2026
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)Mar 13, 2026
- Integrated Core Strategies (Us) LlcPassive (13G)Mar 13, 2026
- Easom EricPassive (13G)Feb 13, 2026
- Bml Investment Partners, L.P.Activist (13D)Jun 18, 2025
- Coastlands Capital Partners LpPassive (13G)Jun 4, 2025
- Adjuvant Global Health Technology Fund, L.P.Passive (13G)Feb 28, 2025
- Ra Capital Management, L.P.Passive (13G)Feb 14, 2025
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Feb 14, 2025
- Brii Biosciences LtdPassive (13G)Feb 14, 2025
- Tcg Crossover Gp I, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Aziz KabeerDirector | Apr 10, 2026 | Grant | 3,775 | $0.00 |
| Marks Gilbert LynnDirector | Apr 10, 2026 | Grant | 3,775 | $0.00 |
| Martin Patricia A.Director | Apr 10, 2026 | Grant | 1,192 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 836,372 | 3.5 | -4.9% |
| Apr 30, 2026 | 879,488 | 3.3 | +38.7% |
| Apr 15, 2026 | 633,935 | 1.5 | +12.3% |
| Mar 31, 2026 | 564,275 | 1.4 | -20.7% |
| Mar 13, 2026 | 711,585 | 1.0 | +1122.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Other material eventApr 9, 2026
- Director / officer changeMar 20, 2026
- Results of operationsMar 17, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureMar 10, 2026
- Director / officer changeJan 29, 2026
- Results of operationsNov 12, 2025
- Unregistered equity saleJun 20, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.